Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PureTech Health ( (GB:PRTC) ) has shared an update.
PureTech Health’s founded entity, Vedanta Biosciences, has published additional Phase 2 results for its lead candidate, VE303, in Nature Medicine. VE303, a Live Biotherapeutic Product targeting recurrent Clostridioides difficile infection (rCDI), has shown promise in reducing CDI recurrence by restoring a healthy gut microbiome. These findings support the ongoing Phase 3 RESTORATiVE303 study, which aims to further evaluate VE303’s efficacy and safety, with topline data expected in 2026. The study’s implications could enhance Vedanta’s positioning in the gastrointestinal disease therapeutics market.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to address devastating diseases. It has formed a broad pipeline through its research and development team and a network of scientists, clinicians, and industry leaders.
YTD Price Performance: -6.79%
Average Trading Volume: 741,541
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £335.2M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.
